Structure Therapeutics’ (GPCR) Overweight Rating Reiterated at Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $65.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 66.62% from the company’s previous close.

Several other analysts have also recently weighed in on the stock. BMO Capital Markets boosted their price objective on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, June 7th. JPMorgan Chase & Co. began coverage on Structure Therapeutics in a report on Tuesday, May 21st. They set an “overweight” rating and a $65.00 price target on the stock. Finally, JMP Securities decreased their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $84.63.

Structure Therapeutics Price Performance

GPCR stock traded down $1.83 during midday trading on Monday, reaching $39.01. The company had a trading volume of 219,178 shares, compared to its average volume of 787,873. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -50.66 and a beta of -3.52. Structure Therapeutics has a 1-year low of $26.61 and a 1-year high of $75.02. The stock has a 50 day moving average price of $38.12 and a 200-day moving average price of $39.67.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, research analysts anticipate that Structure Therapeutics will post -0.86 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in GPCR. Boxer Capital LLC purchased a new position in shares of Structure Therapeutics in the 4th quarter worth approximately $16,304,000. Avoro Capital Advisors LLC raised its stake in shares of Structure Therapeutics by 133.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after purchasing an additional 1,333,333 shares during the period. Octagon Capital Advisors LP purchased a new position in shares of Structure Therapeutics in the 4th quarter worth about $16,875,000. Bellevue Group AG increased its holdings in Structure Therapeutics by 2,858.7% during the first quarter. Bellevue Group AG now owns 363,926 shares of the company’s stock worth $15,598,000 after buying an additional 351,626 shares during the last quarter. Finally, Capital International Investors purchased a new position in Structure Therapeutics in the fourth quarter valued at about $34,647,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.